AtaiBeckley (ATAI) Net Margin (2021 - 2026)
AtaiBeckley (ATAI) posted quarterly Net Margin of 3121.8% for Q1 2026, down 142206.0% year-over-year from N/an in Q1 2025, and down 83.66% quarter-over-quarter from 1699.74% in Q1 2025.
AtaiBeckley (ATAI) Net Margin (2021 - 2026) Analysis & Trends
AtaiBeckley has reported Net Margin for 5 years, with the latest figure at 8154.07% in Q3 2025.
- Quarterly Net Margin rose 5756093.0% year-over-year to 8154.07% in Q3 2025, while the trailing twelve-month figure through Sep 2025 was 5081.55% (up 3390909.0% YoY) and the FY2024 annual result came in at 48067.86%, down 3523283.0% from the prior year.
- Net Margin for Q1 2026 stood at 3121.8%, down from 1699.74% in the prior quarter.
- The five-year high for Net Margin was 1699.74% in Q1 2025, with the low at 3121.8% in Q1 2026.
- A 5-year average of 55578.23% and a median of 21213.23% in 2021 frame the typical range for Net Margin.
- The sharpest annual moves came in 2023 and 2024: Net Margin soared 19205101 bps in 2023, then slumped 22076944 bps in 2024.
- Over 5 years, Net Margin stood at 21433.04% in 2021, then tumbled by 395 bps to 105989.47% in 2022, then gained by 2 bps to 104155.56% in 2023, then slumped by 212 bps to 324925.0% in 2024, then soared by 97 bps to 8154.07% in 2025.
- According to Business Quant data, Net Margin over the past three periods registered 8154.07%, 3856.61%, and 1699.74% for Q3 2025, Q2 2025, and Q1 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 32.99% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 30.23% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 30.33% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.90% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 30.98% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 12.09% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 12.74% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -3.12% |
| 10 | AtaiBeckley | 2.69 Bn | 2.69 Bn | - | -8,154.07% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -1,908.69% |
| Mar 31, 2026 | -3,121.80% |
| Sep 30, 2025 | -8,154.07% |
| Jun 30, 2025 | -3,856.61% |
| Mar 31, 2025 | -1,699.74% |
| Mar 31, 2025 | -1,699.74% |
| Dec 31, 2024 | -324,925.00% |
| Sep 30, 2024 | -65,715.00% |
| Jun 30, 2024 | -20,993.41% |
| Dec 31, 2023 | -104,155.56% |
| Sep 30, 2023 | 50,855.17% |
| Jun 30, 2023 | -19,210.47% |
| Mar 31, 2023 | -89,554.05% |
| Dec 31, 2022 | -105,989.47% |
| Sep 30, 2022 | -141,195.83% |
| Jun 30, 2022 | -21,540.00% |
| Dec 31, 2021 | -21,433.04% |
| Sep 30, 2021 | -11,713.53% |
| Mar 31, 2021 | 28.91% |